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ABSTRACT 
 
Variants in the transcription factor-7-like 2 
(TCF7L2/TCF4) gene, involved in Wnt 
signaling, are associated with type 2 
diabetes. Loss of Tcf7l2 selectively from 
the β cell in mice has previously been 
shown to cause glucose intolerance and to 
lower β cell mass.  Deletion of the tumour 
suppressor liver kinase B1 (LKB1/STK11) 
leads to β cell hyperplasia and enhanced 
glucose-stimulated insulin secretion, 
providing a convenient genetic model for 
increased β cell growth and function. The 
aim of this study was to explore the 
possibility that Tcf7l2 may be required for 
the effects of Lkb1 deletion on insulin 
secretion in the mouse β cell. Mice bearing 
floxed Lkb1 and/or Tcf7l2 alleles were 
bred with knock-in mice bearing Cre 
recombinase inserted at the Ins1 locus 
(Ins1Cre), allowing highly β cell-selective 
deletion of either or both genes. Oral 
glucose tolerance was unchanged by the 
further deletion of a single Tcf7l2 allele in 
these cells. By contrast, mice lacking both 
Tcf7l2 alleles on this background showed 
improved oral glucose tolerance and 
insulin secretion in vivo and in vitro 
compared to mice lacking a single Tcf7l2 
allele. Bi-allelic Tcf7l2 deletion also 
enhanced β cell proliferation, increased β 
cell mass and caused changes in polarity 
as revealed by the “rosette-like” 
arrangement of β cells. Tcf7l2 deletion 
also increased signaling by Target of 
Rapamycin (mTOR), augmenting 
phospho-ribosomal S6 levels. We 
identified a novel signaling mechanism 
through which a modifier gene, Tcf7l2, 
lies on a pathway through which LKB1 
acts in the β cell to restrict insulin 
secretion.  
 
 
Type 2 diabetes currently affects 415 
million individuals worldwide and this 
number is expected to rise to >600 million 
by 2040 (www.diabetesatlas.org). 
Pancreatic β cell failure is an essential, if 
still poorly understood, component of 
disease development and progression (1). 
 
Genome-wide association studies (GWAS) 
have identified more than 100 loci 
associated with disease risk (2), with the 
majority affecting insulin secretion rather 
than the action of the hormone. Although 
in a few cases the likely effector transcript 
has been identified (3,4), for most loci 
neither the causal gene, nor its mechanism 
of action at the cellular level, has been 
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defined. Of the commonly inherited risk 
variants, those in the T-cell factor 7–like-2 
(TCF7L2/TCF4) gene, including 
rs7903146, display amongst the highest 
odds ratio for exaggerated type 2 diabetes 
risk (~1.2/allele) (5). The identified single 
nucleotide polymorphism (SNP) 
rs7903146 is located in the third intron of 
TCF7L2 and has been estimated to 
contribute to 10-25% of all cases of 
diabetes lean patients (6) TCF7L2 lies at 
the foot of the wingless (Wnt) signaling 
pathway activated both by Wnt ligands 
and by certain growth factors (e.g. insulin, 
IGF-1) which act through receptor tyrosine 
kinases (7). In the presence of Wnt 
ligands, a signaling cascade results in 
stabilization and nuclear localization of β-
catenin, which interacts with T cell-
specific factor/lymphoid enhancer-binding 
factor (TCF/LEF) to control transcription 
of target genes. In the absence of Wnt 
ligands, β-catenin is degraded by protein 
complexes including axin-2 and glycogen 
synthase kinase 3β (GSK-3β) (8). 
 
Several studies have explored the role of 
Tcf7l2 in insulin secretion in model 
systems. Thus, inhibition of TCF7L2 
activity in human or in rat insulinoma cell 
line (9,10) inhibited insulin secretion in 
response to glucose. Likewise, deletion of 
the Tcf7l2 gene selectively in the β cell in 
mice (11,12) reduced insulin production in 
older animals and impaired the expansion 
of β cell mass in response to a high fat diet 
(11,12). Finally, in a separate study (13), 
re-expression of TCF7L2 on a null 
background improved glucose tolerance. 
Importantly, the degree to which the action 
of disease risk variants on the β cell may 
be context-dependent is unclear. Thus, 
TCF7L2 variants could have different 
patho-physiological effects among the five 
different subpopulations of diabetic 
patients identified in a recent study (14). 
The mechanisms, including the genetic 
drivers, behind these differences remain 
obscure. 
 
Here, we have explored the impact of 
Tcf7l2 deletion in a model of β cell 
expansion driven by artificially enhanced 
growth factor signaling. Several earlier 
observations have suggested that a 
reciprocal relationship may exist between 
the tumour suppressor Liver Kinase B1 
LKB1/STK11 (LKB1) and TCF7L2 
signaling in other systems. Firstly, the 
LKB1/STK11 homologue XEEK1 is 
required for Wnt signaling in Xenopus 
laevis, and acts by phosphorylating and 
inactivating glycogen synthase kinase-3 
(GSK3) (40).  Moreover, in Peutz-Jeghers 
syndrome, Wnt signaling activation is 
correlated to LKB1 expression (41). 
Similarly, in oesophageal carcinoma 
patients, LKB1 is down-regulated while 
Wnt target genes are up-regulated through 
inhibition of GSK3β activity (42). We 
(15,16), and others (17,18), have shown 
previously that inactivation of LKB1, in 
the β cell leads to a substantial increase in 
insulin production and improved glucose 
tolerance. LKB1 is a tumour suppressor 
mutated in Peutz-Jeghers syndrome, a 
premalignant condition characterised by 
hamartomatous polyps and an increased 
risk of all cancers (19,20). Although the 
mechanisms involved remain to be fully 
elucidated, increases in β cell mass (15), 
changes in the signaling pathways 
activated by glucose (16,21), and 
alterations in cellular morphology and 
polarity (15,17,18) all appear to play a role 
in enhancing insulin secretion in the Lkb1-
null β cell. Acting via the fuel-sensitive 
enzyme AMP-activated protein kinase 
(AMPK), and the Tuberous Sclerosis 
Complex TSC1-TSC2, LKB1 also inhibits 
mammalian target of rapamycin (mTOR) 
signaling to restrict protein synthesis and 
cell division (22). This pathway may 
oppose β cell expansion in the adult, since 
AMPK is likely to be active in these cells 
in the fasting state (23,24).   
 
To explore the above possibilities, we 
have used an epistasis approach to 
examine the impact on the pancreatic β 
cell of deleting Tcf7l2 in the absence of 
Lkb1 alleles. We show that, in contrast to 
the action of Tcf7l2 ablation to impair 
insulin secretion in wild-type mice, loss of 
this transcription factor on an Lkb1 null 
background further increases insulin 
secretion, β cell size, β cell mass, and 
augments mTOR activity, consistent with 
a role for TCF7L2 as an inhibitor of 
mTOR signaling. 
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Results 
Generation of β cell specific Lkb1/Tcf7l2 
double knockout mice 
To study the impact of the deletion of 
Tcf7l2 and Lkb1 in the pancreatic β cell, 
we established breeding pairs on a mixed 
background (C57BL/6J, FVB/NJ and  
129sS1/SvlmJ) to produce offspring 
deleted for Lkb1 and / or Tcf7l2 selectively 
in the β cell using the highly selective Cre 
deleter strain Ins1Cre in which Cre 
recombinase is inserted into the Ins1 locus 
(25,26) (Figure 1A and B). Deletion at 
other sites, including the brain, is minimal 
in this model and, importantly, the 
transgene does not carry the human 
growth hormone minigene present in 
alternative Cre strains (e.g. RIP2.Cre) 
(27). Consequently, effects of Ins1Cre 
expression alone on glucose homeostasis 
are not observed.  Since a strategy 
generating all possible genotypes would 
have produced mice homozygous for 
deletion of both alleles at a frequency of 1 
per 64 pups, we designed instead two-
separate breeding colonies to reduce 
animal numbers, in accordance with the 
3Rs. The following offspring were 
produced and named as follow (group 1): 
control (Ins1Cre-/-:Lkb1f/f:Tcf7l2f/+), 
βLkb1-KO (Ins1Cre+/-:Lkb1f/f:Tcf7l2+/+), 
and βLkb1-KO-Tcf7l2-het (Ins1Cre+/-
:Lkb1f/f:Tcf7l2f/+; Figure 1A). The second 
breeding strategy (group 2) generated 
littermates βLkb1-KO-Tcf7l2-het 
(Ins1Cre+/-:Lkb1f/f:Tcf7l2f/+) and βLkb1-
Tcf7l2-dKO (Ins1Cre +/-: Lkb1f/f:Tcf7l2f/f ; 
group 2,  Figure 1B).  
 
We first measured Lkb1 and Tcf7l2 gene 
expression in isolated islets using RT-
qPCR analysis. The level of endogenous 
Lkb1 mRNA was strongly decreased in the 
presence of Cre transgene when one single 
or both Tcf7l2 alleles were floxed, as 
expected.  Likewise, the level of Tcf7l2 
mRNA was decreased when both alleles 
were floxed (βLkb1-Tcf7l2-dKO) 
compared to control. Importantly, we 
observed no significant differences in the 
level of Lkb1 and Tcf7l2 mRNA between 
βLkb1-KO-Tcf7l2-het mice from either 
group 1 or 2. Of note, deletion of Lkb1 
significantly increased Tcf7l2 expression 
when both Tcf7l2 alleles were present in 
βLkb1-KO mice (Figure 1C and D). 
Likewise, we observed decreased LKB1 
and TCF7L2 protein expression in isolated 
islets from βLkb1-KO, βLkb1-KO-Tcf7l2-
het and βLkb1-Tcf7l2-dKO compared to 
control islets (Figure 1E). 
 
Deletion in the β cell of two Tcf7l2 alleles 
in an Lkb1 null background improves 
oral glucose tolerance and insulin 
secretion  
Consistent with previous findings (15-
18,25), deletion of both Lkb1 alleles in the 
β cell improved glucose tolerance in mice 
aged 8 weeks (Figure 2A, B). These 
changes were not associated with any 
alteration in body weight (Figure S1A). 
Glucose tolerance was not further affected 
by the additional deletion of a single 
Tcf7l2 allele (Figure 2A, B). Deletion of 
Lkb1 alone also lowered fed glycemia, and 
this action was attenuated by the 
additional deletion of Tcf7l2 (Figure S1B). 
Insulin sensitivity was unchanged by 
deletion of a single Tcf7l2 allele (Figure 
S1D). 
 
As previously described (15-18,25), Lkb1 
deletion substantially increased insulin 
release in response to glucose in vivo 
(Figure 2C). Interestingly, glucose-
stimulated insulin secretion in vitro only 
tended to increase on an Lkb1 null 
background compared to control (Figure 
2D).  Mono-allelic Tcf7l2 deletion had 
little further impact on these changes such 
that the glycemic phenotype of βLkb1-
KO-Tcf7l2-het did not differ from βLkb1-
KO mice in vivo, but insulin release was 
enhanced in vitro (Figure 2C and D). In 
contrast, when βLkb1-KO-Tcf7l2-het mice 
were compared to homozygous βLkb1-
Tcf7l2-dKO animals deleted for both 
Tcf7l2 alleles we observed a further 
improvement in glucose tolerance (Figure 
3A, B), but unchanged, body weight, fed 
glycemia and insulin sensitivity (Figure 
S2A, C, E). A substantial (~2-fold) 
increase in acute insulin release in 
response to glucose injection was also 
observed in vivo (Figure 3C, D) when 
comparing βLkb1-Tcf7l2-dKO with 
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βLkb1-KO-Tcf7l2-het littermates.  
Likewise, comparing islets isolated from 
mice deleted for both versus a single 
Tcf7l2 allele, insulin secretion was 
significantly increased in response to 
elevated glucose but not to depolarisation 
with KCl (Figure 3E). Thus, deletion of 
Tcf7l2 on a Lkb1 null background exerts 
an effect whose direction is opposite to 
that seen in control islets (11,12). In 
females, deletion of one or two Tcf7l2 
alleles on a Lkb1 null background did not 
affect oral glucose tolerance, insulin 
sensitivity, fed glycemia and body weight 
compared to Lkb1 deletion only (βLkb1-
KO; Supplemental Figure S2). 
 
Next, we sought to explore intracellular 
free calcium (Ca2+) dynamics to elucidate 
whether these may be altered and 
contribute to the enhanced insulin 
secretion. Islets derived from βLkb1-KO 
mice displayed a delayed and decreased 
response to high glucose in free cytosolic 
Ca2+ increases compared to control 
animals (Figure 4A and B). A similar 
degree of impairment was observed after 
the additional deletion of a single Tcf7l2 
allele. Interestingly, islets from βLkb1-KO 
mice showed a decreased response to 
depolarisation with KCl compared to 
control mice, whereas βLkb1-KO-Tcf7l2-
het islets displayed a similar response to 
KCl compared to control islets (Figure 4A 
and C). In group 2, no difference in 
response to high glucose or KCl was noted 
between islets from βLkb1-KO-Tcf7l2-het 
and βLkb1-Tcf7l2-dKO mice (Figure 4D, 
E and F). 
 
Impact of Lkb1 and Tcf7l2 deletion on 
islet morphology 
We next examined β cell size, and the 
distribution of β cells within the islet, in 
pancreatic slices (Figure 5A, B). Cellular 
proliferation was also assessed through 
Ki67 staining (Figure 5C). As previously 
reported (15-18,25), deletion of Lkb1 
increased the number of “rosette-like” 
structures within each islet, as identified 
using the adherens junction marker E-
cadherin, likely reflecting a change in 
cellular polarity (Figure 6A, B) (see 
(15,18). The number of rosette structures 
was not significantly affected by deletion 
of a single Tcf7l2 allele whilst the deletion 
of both alleles tended (p=0.055) to 
increase this number, a change which may 
also contribute to the enhanced secretion 
observed (15,18). 
 
β Cell mass did not show any significant 
differences after Lkb1 deletion, deletion of 
a single Tcf7l2 allele had no further effect 
(Figure 6C). In contrast, deletion of both 
Tcf7l2 alleles caused a substantial (>30%) 
and significant increase in β cell mass as 
examined in βLkb1-Tcf7l2-dKO versus 
βLkb1-KO-Tcf7l2-het littermates. 
Correspondingly, β cell proliferation, 
examined by Ki67 staining, was not 
affected by Lkb1 deletion alone, nor the 
loss of a single Tcf7l2 allele, but 
significantly increased when two Tcf7l2 
alleles were deleted (Figure 5C and Figure 
6E, F). β cell size, as assessed by 
comparing islet volume to the number of 
DAPI-labelled nuclei/islet, was 
significantly increased by Lkb1 deletion, 
but not further affected by either mono- or 
bi-allelic deletion of Tcf7l2 (Figure 6 G, 
H). 
 
Impact of Tcf7l2 deletion on mTOR 
signaling 
As previously described (15,17), mTOR 
signaling is implicated in β cell 
hypertrophy when Lkb1 is deleted. We 
therefore examined whether Tcf7l2 
deletion may impact mTOR signaling. 
Whereas deletion of Lkb1 alone had no 
effect on the levels of phospho-ribosomal 
protein subunit S6 (rpS6) (Figure 7A, B, 
D), a significant increase was observed in 
βLkb1-Tcf7l2-dKO vs βLkb1-Tcf7l2-het 
islets by immunostaining of pancreatic 
slices (Figure 7A, C), and confirmed by 
Western (immuno-) blotting (Figure 7E). 
  
Regulation of Wnt signaling 
Finally, we explored the effects of LKB1 
and TCF7L2 deletion on genes in the 
Wnt/β-catenin pathway. We found that β-
catenin, the transcriptional activator for 
the TCF family of transcription factors, 
and axin-2, a negative loop regulator of 
Wnt signaling, tend to be downregulated 
in the absence of LKB1 (Figure 8A). 
However, axin-2 was upregulated by 
LKB1 and TCF7L2 deletion (Figure 8B). 
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Therefore, it is possible that a cross-talk 
exists between LKB1 and Wnt/TCF7L2 
signaling in pancreatic islets and that this 
could be involved in controlling β cell 
proliferation. Furthermore, it is possible 
that Lkb1 could be a regulator of Wnt 
signaling and that TCF7L2 is involved for 
loop regulation of Wnt signaling involved 
in proliferative signaling induced by Wnt 
ligands.   
 
Discussion 
The overall aim of the present study was 
to determine whether, under conditions of 
exaggerated β cell proliferation, the role of 
Tcf7l2 may differ from that previously 
described in animals placed under 
metabolic stress imposed by aging or by a 
high fat diet (11,12). To this end we used a 
mouse model in which Lkb1 was deleted 
selectively in β cells mimicking, at least in 
part, changes during early development 
(28,29), pregnancy (30,31) or insulin 
resistance ("compensation") prior to the 
onset of type 2 diabetes (32,33). This has 
seemed an important question given that 
apparent differences in action have 
previously been described for other 
GWAS-identified type 2 diabetes genes, 
such as SLC30A8 (34-36) when modelled 
in mice.  
 
Strikingly, we demonstrate that the 
direction of the effect of Tcf7l2 deletion is 
reversed under these conditions (β cell 
hyper-function) versus those seen under 
metabolic stress (11,12). Given that 
TCF7L2 is normally considered to be a 
positive regulator of the cell cycle, and 
thus pro-proliferative (37,38), this result 
was unexpected. We therefore considered 
carefully the possibility that this might be 
due to alterations elsewhere in the genome 
given that the Lkb1 alleles (FVB/N/129S1) 
were carried by animals with a slightly 
different genetic background to the floxed 
Tcfl72 strain (C57BL/6J) used (see 
Supplemental Table S1). Although this 
possibility cannot be excluded absolutely 
we believe it is unlikely given that both 
FVB/N (39) and 129S1 (40) animals 
display similar glucose tolerance on a 
regular chow diet to C57BL/6 mice.  
 
As an alternative explanation, we 
speculated that Tcf7l2 acts as a negative 
regulator of mTOR signaling. This view 
was supported by the data shown in Figure 
7, which demonstrated increased mTOR 
signaling after deletion of both, but not a 
single, Tcf7l2 allele. Interestingly, in the 
present study we saw relatively little effect 
of Lkb1 deletion on mTOR signaling in the 
presence of Tcf7l2, despite the predicted 
activation of the downstream TCS1/TCS2 
complex in the absence of AMPK activity 
(22). Nevertheless, and interestingly, loss 
of TCF7L2 impacted the alterations in β 
cell apical-basolateral polarity observed 
after Lkb1 ablation (15-18,25), which lead 
to alterations in the number of “rosette” 
structures. The latter changes have 
previously been ascribed to alterations in 
signaling by the AMPK-related kinase 
MARK2/Par1b (18).  
 
Interestingly, increased Tcf7l2 and 
decreased β-catenin mRNA levels were 
also observed after Lkb1 deletion in the 
present study, providing evidence for an 
interaction between these genes in the β 
cell wherein LKB1 represses Tcf7l2 
expression (Figure 8). Morever, we found 
that axin-2 was regulated positvely and 
negatively, respectively, by Lkb1 and 
Tcf7l2. 
 
We also noted that deletion of Tcf7l2 on 
an Lkb1 null background resulted both in 
changes in β cell growth (i.e. hypertrophy 
and hyperplasia) but also increased β cell 
function (secretion of insulin as 
normalized to total insulin content). While 
increased mTOR signaling provides a 
likely mechanism for the former, the 
mechanisms driving increased insulin 
secretion remain unclear. In recent studies, 
we (16) and others (21) demonstrated that 
loss of LKB1 signaling resulted in marked 
alterations in glucose signaling to ATP 
generation and calcium dynamics, such 
that the so-called "amplifying" pathway, of 
insulin secretion (41,42), possibly 
mediated by enhanced synthesis of 
glutamate and other amino acids, became 
the predominant means through which 
hormone release was activated in response 
to the sugar. The present study confirmed 
these findings (Figure 4A).  Importantly, 
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we observed no evident improvement in 
Ca2+ dynamics in response to elevated 
glucose or KCl after deletion of a single or 
both Tcf7l2 alleles. This observation 
argues against the view that Tcf7l2 
deletion leads to a reversion to a more 
conventional route for glucose-stimulated 
insulin secretion, chiefly reliant on the 
closure of ATP-dependent K+ channels 
(43) and calcium influx. Instead, the new 
findings point towards a further 
enhancement of the amplifying pathways 
for insulin secretion in β cells lacking both 
Tcf7l2 alleles in the absence of Lkb1.  
 
The present data may also provide a 
mechanistic underpinning for other 
findings in the literature which have 
pointed to a possible interaction between 
nutrient levels and TCF7L2 action. For 
example, the action of TCF7L2 risk (T) 
allele rs7903146 was dependent on plasma 
glucose levels during oral glucose 
tolerance tests (44), with deleterious 
actions being most apparent at high 
glucose, and even tending to be protective 
at low glucose. We would note that 
although the direction of this effect might 
appear to be the reverse of that reported 
here in mice, the above study is likely 
chiefly to have interrogated the actions of 
incretins on insulin secretion, which were 
not examined here. Nevertheless, glucose-
dependent suppression of AMPK activity, 
likely to mimic the effect of Lkb1 deletion 
on mTOR activity, may provide a means 
through which changes in glycemia 
modulate the direction of effect of 
TCF7L2 variants on type 2 diabetes risk.  
In summary, we demonstrate here that 
Tcf7l2 acts as a modifier gene for Lkb1 in 
the β cell, affecting islet polarity, cellular 
proliferation and mass via mTOR 
signaling. These findings may be relevant 
for our understanding of the actions of 
human TCF7L2 variants on type 2 
diabetes risk in different individuals and 
settings (14). 
 
Experimental procedures 
Generation of mutant mice lacking 
LKB1 and TCF7L2 selectively in 
pancreatic β cells. 
Mice homozygous for the floxed 
Lkb1/Stk11 gene (mixed FVB/129S1 and 
C57BL/6 background) (15) were crossed 
to mice homozygous for floxed (f/f) Tcf7l2 
alleles (C57BL/6 background) (12). The 
resulting double heterozygotes (Lkb1f/+: 
Tcf7l2f/+) were crossed with double 
heterozygous mice and the latter then bred 
with mice expressing Cre recombinase at 
the Insulin 1 locus (Ins1.Cre) (25,26). 
Subsequently, two-separate breeding 
colonies were established to produce the 
following offspring, and named as follow 
(group 1): control (Ins1Cre-/-
:Lkb1f/f:Tcf7l2f/+), βLkb1-KO (Ins1Cre+/-
:Lkb1f/f:Tcf7l2+/+), and βLkb1-KO-Tcf7l2-
het (Ins1Cre+/-:Lkb1f/f:Tcf7l2f/+; Figure 
1A). The second breeding strategy 
generated littermates βLkb1-KO-Tcf7l2-
het (Ins1Cre+/-:Lkb1f/f:Tcf7l2f/+) and 
βLkb1-Tcf7l2-dKO (Ins1Cre +/-: 
Lkb1f/f:Tcf7l2f/f ; group 2,  Figure 1B). 
Genetic background of the resulting 
crosses was quantified by SNP genome 
scanning analysis (Jax® Laboratories; 
Table S1). 
 
Mouse maintenance and diet 
Animals were housed 2-5 per individually-
ventilated cage in a pathogen-free facility 
with 12 h light/dark cycle and had free 
access to standard mouse chow diet. 
Unless otherwise stated, data presented are 
those obtained using male mice. All in 
vivo procedures described were performed 
at the Imperial College Central Biomedical 
Service and approved by the UK Home 
Office Animals Scientific Procedures Act, 
1986 (HO Licence PPL PA03F7F07 to 
I.L.). 
 
Measurement of metabolic parameters 
in vivo 
Glucose tolerance was performed on 15 h-
fasted mice after an oral gavage of glucose 
(2 g/kg of body weight). Tail venous blood 
glucose was monitored at 0, 15, 30, 60, 90 
and 120 min after glucose administration. 
Insulin tolerance was performed on 5 h-
fasted mice after an intraperitoneal 
injection of insulin (0.75 U/kg of body 
weight; Humulin® S; Lilly, UK). Tail 
venous blood glucose was monitored at 0, 
15, 30, 60 min. In vivo glucose-stimulated 
insulin secretion was assessed after 
intraperitoneal injection of glucose (3 
g/kg) and blood was collected at 0, 2.5, 5 
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and 15 post-injection. Plasma insulin 
levels were measured using a homogenous 
time-resolved fluorescence (HTRF) mouse 
insulin kit (Cisbio, France). 
 
Isolation of mouse islets 
Islets were isolated by digestion with 
collagenase as described (45). In brief, 
pancreata were inflated with a collagenase 
solution (1 mg/mL) and placed in a water 
bath at 37 ⁰C for 12 min. After several 
washes, the islets were purified on a 
Histopaque gradient (Sigma-Aldrich, UK), 
and isolated islets were cultured 24 h in 
RPMI 1640 containing 11.1 mM glucose, 
10% foetal bovine serum and L-glutamine 
(Sigma-Aldrich, UK) and allowed to 
recover overnight. 
 
Ex vivo glucose-stimulated insulin 
secretion 
Insulin secretion assays on isolated mouse 
islets were performed as previously 
described (15). In brief, 10 size-matched 
islets per condition were incubated for 1h 
in Krebs-HEPES-bicarbonate (KHB) 
solution [in mM: 130 NaCl, 3.6 KCl, 1.5 
CaCl2, 0.5 MgSO4, 0.5 KH2PO4, 2 
NaHCO3, 10 HEPES, and 0.1% (wt/vol) 
BSA, pH 7.4] containing 3 mM glucose. 
Subsequently, islets were incubated for 30 
min. in KHB solution with either 3 mM 
glucose, 17 mM glucose or 30 mM KCl. 
Secreted and total insulin were quantified 
using a HTRF insulin kit (Cisbio, France) 
in a PHERAstar reader (BMG Labtech, 
UK) following the manufacturer's 
guidelines. 
 
RNA extraction and quantitative real-
time PCR analysis 
RNA was isolated and purified from fresh 
isolated islets (50-200) with TRIzol 
reagent (Invitrogen, USA) according to the 
manufacturer’s instructions. RNA purity 
and concentration were measured by 
spectrophotometry (Nanodrop, 
Thermofisher) and only RNA samples 
with an absorption ratio between 1.8-2.0 
for 260/280 nm were used. cDNA was 
synthesized using 200 ng of RNA by the 
High-capacity cDNA Reverse 
Transcription kit (Applied Biosystems, 
USA) including random primers. For 
quantitative real-time PCR we used SYBR 
Green PCR master mix (Life 
Technologies, USA) and the primers 
sequences are in supplemental Table S2.  
 
Immunohistochemistry and islet 
morphology 
Isolated pancreata were removed from 
euthanized mice and fixed overnight in 
10% (v/v) formalin and subsequently 
embedded in paraffin wax. Sections (5 
μm) were cut and fixed in superfrost 
slides. Slides were prepared as detailed 
(25). For antigen retrieval before specific 
antigen detection, sections were treated 
with Tris-EDTA buffer, pH 9.0, at 95°C 
for 20 min. Primary antibodies used were 
anti-guinea pig insulin (1:200; Dako, 
USA), anti-mouse glucagon (1:1000; 
Sigma-Aldrich, UK), anti-E-cadherin 
(1:100; Cell Signaling Technology, USA), 
anti-Ki67 (1:200; Abcam, UK). Slides 
were visualized using an Axiovert 200 M 
microscope (Zeiss, Germany) with Alexa 
Fluor 488 goat anti-guinea pig IgG, Alexa 
Fluor 568 donkey anti-mouse IgG, Alexa 
Fluor 488 goat anti-rabbit IgG or Alexa 
Fluor 568 goat anti-guinea-pig IgG 
(Invitrogen, UK). ImageJ software 
(Wayne Rasband, National Institute of 
Mental Health) was used to calculate the β 
cell mass and size. We determined the 
percentage of pancreatic surface that was 
insulin or glucagon positive, as measured 
in 4 sections separated by 75 μm in the z-
axis from six to seven mice of each 
genotype. For Ki-67 and E-cadherin 
detection, pancreata from three 10-week-
old mice in each genotype were examined. 
At least three 5-μm sections per mouse at 
least 150 μm apart were analysed.   To 
quantify the number of “rosette-like” 
structures (i.e., 8–10 cells arranged 
concentrically around an identifiable 
central “core”) in islets (15), we used E-
cadherin and DAPI staining of pancreatic 
sections. Structures were included where 
the void at the center was negative for 
DAPI. Ten islets per mouse and three mice 
per genotype were assessed. 
 
Western (immuno-) blotting 
After isolation, islets were collected and 
lysed in ice-cold buffer (150 mM NaCl, 10 
mM Tris-HCl pH 7.2, 0.1% SDS, 1% 
deoxycholate, 5 mM EDTA, 1% Triton-
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X100) containing protease inhibitor 
cocktail (Roche, UK) and phosphatase 
inhibitors (Sigma-Aldrich, UK). Lysates 
from 125 islets were denatured for 5 min. 
at 95⁰C in Laemmli buffer, and resolved 
by 10% SDS-PAGE, and transferred to 
PVDF membranes before immunoblotting. 
Intensities were quantified using ImageJ. 
 
Antibodies 
Antibodies used in Western (immuno-)blot 
analysis and immunohistochemistry were 
the following: rabbit anti-phospho-S6 
Ribosomal Protein (Ser235/236) (Cell 
signaling Technology, USA), mouse anti-
α-tubulin (Sigma-Aldrich, UK), rabbit 
anti-E-cadherin (Cell signaling 
Technology, USA), guinea-pig anti-insulin 
(Dako, USA), mouse anti-glucagon 
(Sigma-Aldrich, UK), and rabbit anti-Ki67 
(Abcam, UK). 
 
Measurement of intracellular free 
calcium 
Whole isolated islets were incubated with 
fura-8AM (Invitrogen) for 45 min at 37⁰C 
in KHB containing 3 mmol/L glucose. 
Fluorescence imaging was performed 
using a Nipkow spinning disk head, 
allowing rapid scanning of islet areas for 
prolonged periods of time with minimal 
phototoxicity. Velocity software 
(PerkinElmer Life Sciences) provided 
interface while islets were kept at 37⁰C 
and constantly perifused with KHB 
containing 3 mmol/L or 17 mmol/L 
glucose or 20 mmol/L KCl. For each 
experiment we used 16-29 islets. Imaging 
data were analysed with ImageJ software 
using an in-house macro (46). 
 
Statistical analysis 
GraphPad Prism 7.0 was used for 
statistical analysis. Statistical significance 
was evaluated by the two-tailed paired 
Student t test and one- or two-way 
ANOVA with a Bonferroni or Tukey post 
hoc test when appropriate. All data are 
shown as means ± SEM. P values of <0.05 
were considered statistically significant. 
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Figure 1: Breeding strategy for the generation of Lkb1/Tcf7l2 deletion mutants in the β cell and 
confirmation of the mouse model. A: Littermate pups from group 1 display 3 different genotypes: 
control as Ins1Cre -/-: Lkb1 f/f: Tcf7l2 f/+, Lkb1 deletion only as βLkb1-KO (Ins1Cre +/-: Lkb1 f/f: 
Tcf7l2 +/+), and one single Tcf7l2 allele deleted in Lkb1 null background as βLkb1-KO-Tcf7l2-het 
(Ins1Cre +/-: Lkb1 f/f: Tcf7l2 f/+). B: Littermate pups from group 2 display two different genotypes; one 
single Tcf7l2 allele deleted in a Lkb1 null background as βLkb1-KO-Tcf7l2-het (Ins1Cre +/-: Lkb1 f/f: 
Tcf7l2 f/+) and two single Tcf7l2 alleles deleted in Lkb1 null background as βLkb1-Tcf7l2-dKO 
(Ins1Cre +/-: Lkb1 f/f: Tcf7l2 f/f). C: RT-qPCR expression of Lkb1 mRNA in isolated islets (n=5-6 
mice/genotype). D:  RT-qPCR expression of Tcf7l2 mRNA in isolated islets (n=5-9 mice/genotype). 
E: Western blotting for TCF7L2 and LKB1 in isolated islets (n=2 mice/genotype). Error bars 
represent the mean of ± S.E.; *p<0.05, ****p<0.0001. 
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Figure 2: Monoallelic deletion does not affect Lkb1 deletion-mediated improvements in glucose 
tolerance and augmented insulin secretion in males. 
A: Oral glucose (2 g/kg) tolerance measurements were performed as described under Materials and 
Methods. n=9-12 mice/genotype; P value was statistically determined by a two-way ANOVA test 
with a Bonferroni post-test. **p<0.01, ****p<0.0001 βLkb1-KO vs control; †p< 0.05, ††††p<0.0001 
βLkb1-KO-Tcf7l2-het vs control; p=0.623 βLkb1-KO vs βLkb1-KO-Tcf7l2-het. B: Area under the 
curve (AUC) for oral glucose tolerance tests (*p<0.05 βLkb1-KO vs control, **p<0.01 βLkb1-KO-
Tcf7l2-het vs control).C: Insulin plasma levels were measured in vivo 15 minutes after intraperitoneal 
injection of glucose (3 g/kg) (n=7-9 mice/genotype; *p<0.05, **p<0.01 vs 15min-control. D: Insulin 
secretion in vitro was measured from groups of 10 size-matched isolated islets during static 
incubation (Research design and Methods) and at the indicated glucose or KCl concentrations (n=4 
independent experiments; **p<0.01 βLkb1-KO-Tcf7l2-het vs βLkb1-KO, ***p<0.001 βLkb1-KO-
Tcf7l2-het vs control); Error bars represent the mean of ± S.E.; ns=not significant. 
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Figure 3: Deletion of both Tcf7l2 alleles potentiates the effects of Lkb1 deletion on glucose 
tolerance and insulin secretion in males. 
Experiments were performed as described in the legends to Figure 2 (A, B) oral glucose tolerance 
n=7-11 mice/genotype. Insulin plasma levels were measured in vivo 2.5, 5 and 15 minutes after 
intraperitoneal injection of glucose (3 g/kg) (C, D) n=7-8 mice/genotype, E: Insulin secretion in vitro 
was measured from groups of 10 size-matched isolated islets during static incubation (Research 
design and Methods) and at the indicated glucose or KCl concentrations; n=4-6 mice/genotype; 
*p<0.05, **p<0.01, ****p<0.0001. Grey open circle as βLkb1-KO-Tcf7l2-het, black circle as βLkb1-
Tcf7l2-dKO; Error bars represent the mean of ± S.E. 
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Figure 4: Deletion of one or two Tcf7l2 alleles did not further alter Ca2+ dynamics in response to 
glucose but restored responses to KCl in males. A: Changes in free cytosolic Ca2+ in response to 3 
mmol/L glucose (3G), 17 mmol/L glucose (17G) and 20 mmol/L KCl in group 1. B: Quantification of 
area under the curve for glucose responses. C: Quantification of area under the curve for KCl 
responses. D: Free cytosolic Ca2+ changes in response to 3 mmol/L glucose (3G), 17 mmol/L glucose 
(17G) and 20 mmol/L KCl in group 2. E: Quantification of area under the curve for glucose 
responses. F: Quantification of area under the curve for KCl responses. Each plot represents the 
average of 16-29 islets, n=3 per genotype. *p<0.05, **p<0.01, ****<p0.0001; Error bars represent the 
mean of ± S.E.; ns=not significant. 
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Figure 5: Impact of Lkb1 or Tcf7l2 deletion on islet topography in males. Representative 
immunohistochemistry results of pancreatic sections stained for β cell mass (A: insulin, 1:200, green; 
glucagon, 1:1000, red), for an adherens junction marker (B: E-cadherin, 1:100, green) and for a 
proliferation marker (C: Ki-67, 1:100, green). Rosette-like structure are localized in the white dotted 
line square and a representative image of a rosette-like structure is zoomed in column B in control 
mouse. Scale bar 100 μm. 
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Figure 6: Effects of Lkb1 or Tcf7l2 deletion on β cell size and mass in males.  
A, B: Rosette-like structure count per islet; n=3 mice/genotype in the group 1 (A) and in group 2 (B). 
C, D: β cell mass is the ratio of insulin positive staining to the total pancreatic surface and pancreas 
weight, n=6-7 mice/genotype. E, F: Quantification of Ki67 positive and insulin positive cells, based 
on 10-15 islets per pancreas; n=3-4 mice/genotype. G, H: Mean β cell size measured as the ratio of the 
insulin positive staining surface area to the number of β cells (n=3-4 mice/genotype) in the group 1 
(G) and in group 2 (H). *p<0.05 **p<0.01. White bars as control, black bars as βLkb1-KO, grey bars 
as βLkb1-KO-Tcf7l2-het (group 1), hatched grey bars as βLkb1-KO-Tcf7l2-het (group 2) and dots 
black bars as βLkb1-Tcf7l2-dKO; Error bars represent the mean of ± S.E.; ns=not significant. 
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Figure 7: Deletion of Tcf7l2 increases mTOR activity in Lkb1 null islets from males.  
A: Representative immunofluorescence staining of pancreatic sections from random-fed 10-week-old 
males using rabbit anti-phospho-ribosomal protein S6 (Ser235/236) (P-rpS6; 1:100; red) and guinea-
pig anti-insulin antibodies (1:200; red). White arrows represent p-rpS6 and insulin colocalization. 
Scale bar, 100 µm. B/C: Quantification of p-rpS6 positive staining of total β cells per islet, based on 
15-20 islets per pancreas from n=4-5 mice/genotype. White bars as control, black bars as βLkb1-KO 
grey bars as βLkb1-KO-Tcf7l2-het (B), hatched grey bars as βLkb1-KO-Tcf7l2-het (C) and dots black 
bars as βLkb1-Tcf7l2-dKO. D/E: Mouse pancreatic islets were isolated from animals of group 1 (D) 
and group 2 (E). After an overnight incubation in 11 mmol/L of glucose in RPMI media, isolated 
islets were collected and lysates from 125 islets were analysed by immunoblotting with anti-
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phosphorylated (p-S6) and total (tot-S6) ribosomal protein-S6 (Ser235/236) and anti-tubulin for group 
1 (D) and group 2 (E). Error bars represent the mean of ± S.E.; *p<0.05; ns=not significant. 
 
Figure 8: Wnt signalling is partly dependent on LKB1 and TCF7L2 in males. Wnt signalling 
target genes (GSK-3β, β-catenin and axin-2) expression was assessed by RT-qPCR in isolated islets 
from group 1 (A) and group 2 (B); n=2-3 mice/genotype. Error bars represent the mean of ± S.E.; 
*p<0.05. 
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